Anti-VEGF Therapy in Osteoarthritis and Associated Pain
Anti-VEGF Therapy in Osteoarthritis and Associated Pain
批准号:
9124190
负责人:
John L Hamilton
金额:
$4.36万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2017-12-31
关键词:
AblationAffectAfferent NeuronsAngiogenic FactorAnimalsAntibodiesArthralgiaArthritisAssesAttenuatedBehavioralBiochemicalBone SpurCartilageChondrocytesClinicalCombined Modality TherapyDataDegenerative polyarthritisDevelopmentDiseaseDoseEmployee StrikesEnzymesFDA approvedFibroblastsFilamentGene ExpressionGrowthHalf-LifeHumanHyaluronic AcidHydrogelsHyperplasiaHypertrophyImageImmunofluorescence ImmunologicImmunohistochemistryInflammationInterventionIntra-Articular InjectionsJointsKneeKnee jointKnowledgeLabelLife ExtensionLinkMedial meniscus structureMediatingMediator of activation proteinModelingMusNerve Growth FactorsNeurotrophic Tyrosine Kinase Receptor Type 1PainPain MeasurementPathogenesisPathologic NeovascularizationPathological StagingPathologyPathway interactionsPatientsPharmaceutical PreparationsPublishingReportingRoleSclerosisSeveritiesSignal TransductionSpinal GangliaStagingStaining methodStainsSurfaceSymptomsSynovial CellSynovial FluidSynovial MembraneSynovitisTechnologyTestingTimeTissuesTransgenic MiceVascular Endothelial Growth Factorsafferent nerveaggrecanangiogenesisarticular cartilagebevacizumabbonecartilage degradationcartilage repaircrosslinkdisabilityexperiencehistological imagein vivojoint injurymechanical allodyniapain behaviorpre-clinicalpublic health relevanceranibizumabsynergism
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The role of this project is to assess the role of anti-VEGF therapy in osteoarthritis (OA) progression and associated pain. We will assess the use of low dose intra-articular anti-VEGF antibody at the knee joint in a murine OA model, which will be created by destabilization of the medial meniscus (DMM). Intra-articular administration of anti-VEGF antibody will be tested at different time points of OA progression in different groups. We will assess the role of Hyasis(r) Link hydrogel as slow release agent for anti-VEGF antibody. We will selectively silence gene expression of VEGF at chondrocytes using VEGFfl/fl: Aggrecan-CreERT2 transgenic mice, to asses chondrocyte specific role of VEGF associated OA progression and pain. OA progression will be assessed by Safranin-O stained histologic imaging and OARSI scoring. Longitudinal pain behavior will be assessed by mechanical allodynia, using von Frey filament testing. Specific mediators of VEGF mediated OA progression and pain will be assessed by immunofluorescence imaging and immunohistochemistry at the joint surface, synovium, and dorsal root ganglia. Results of this study will assess the potential o anti-VEGF therapy as a disease modifying OA drug as well as potential for targeting OA associated pain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金